Impact of mineral and bone disorder on healthcare resource use and associated costs in the European Fresenius medical care dialysis population: A retrospective cohort study

BMC Nephrology

Volumn 13, Issue 1, 2012, Pages

  Chiroli, Silvia ^a   Mattin, Caroline ^b   Belozeroff, Vasily ^a   Perrault, Louise ^c   Mitchell, Dominic ^d   Gioni, Ioanna ^b  

^a AMGEN INC   (United States)

^b AMGEN LTD   (United Kingdom)

^c International Market Access Consulting   (Switzerland)

^d International Market Access Consulting   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALCIUM; PARATHYROID HORMONE; PHOSPHATE;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DEATH; DEMOGRAPHY; DRUG USE; EUROPE; FEMALE; FOLLOW UP; FRACTURE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEMODIALYSIS; HOSPITALIZATION; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; RETROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM; SENSITIVITY ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; BONE RESORPTION; COHORT STUDIES; EUROPE; FEMALE; HEALTH CARE COSTS; HEALTH CARE RATIONING; HUMANS; HYPERPARATHYROIDISM; MALE; MIDDLE AGED; PREVALENCE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; RISK FACTORS; UTILIZATION REVIEW;

EID: 84867896472     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-13-140     Document Type: Article

References (29)

1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. National Kidney Foundation, Am J Kidney Dis 2002 39 2 Suppl 1 1 S266 11904577
2. U.S. Renal Data System, USRDS 2010 Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2010
3. Changes in bone mineral parameters, vitamin D metabolites, and PTH measurements with varying chronic kidney disease stages. Patel S, Barron JL, Mirzazedeh M, Gallagher H, Hyer S, Cantor T, Fraser WD, J Bone Miner Metab 2011 29 71 79 10.1007/s00774-010-0192-1 20521154
4. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Disease K, Improving Global Outcomes (KDIGO) CKD-MBD Work Group, Kidney Int 2009 76 Suppl 113 1 S130
5. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. National Kidney Foundation, Am J Kidney Dis 2003 42 4 Suppl 3 1 S201 14520607
6. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK, Kidney Int 2005 67 1179 1187 10.1111/j.1523-1755.2005.00185.x 15698460 (Pubitemid 41623345)
7. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of fracture and need for parathyroidectomy in CKD. Goldsmith D, Kothawala P, Chalian A, Bernal M, Robbins S, Covic A, Am J Kidney Dis 2009 53 1002 1013 10.1053/j.ajkd.2009.02.010 19463763
8. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the dialysis outcomes and practice patterns study. Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prütz K-G, Young EW, Pisoni RL, Kidney Int 2006 70 1358 1366 10.1038/sj.ki.5001754 16929251 (Pubitemid 44435190)
9. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Davies MR, Hruska KA, Kidney Int 2001 60 472 479 10.1046/j.1523-1755.2001.060002472.x 11473629 (Pubitemid 32680895)
10. Are PTH serum levels predictive of coronary calcifications in haemodialysis patients? Coen G, Manni M, Mantella D, Pierantozzi A, Balducci A, Cond S, DiGiulio S, Yancovic L, Lippi B, Manca S, et al. Nephrol Dial Transplant 2007 22 3262 3267 10.1093/ndt/gfm370 17597083 (Pubitemid 350202552)
11. Parathyroid hormone variability parameters for identifying high turnover osteodystrophy disease in hemodialysis patients: an observational retrospective cohort study. De Paola L, Coppolino G, Bolignano D, Buemi M, Lombardi L, Ther Apher Dial 2010 14 566 571 10.1111/j.1744-9987.2010.00822.x 21118364
12. Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease. Raggi P, Kleerekoper M, Clin J Am Soc Nephrol 2008 3 836 843 10.2215/CJN.02910707 18322050
13. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. De Boer IH, Gorodetskaya I, Young B, Hsu CY, Chertow GM, J Am Soc Nephrol 2002 13 2762 2769 10.1097/01.ASN.0000034202.91413.EB 12397047 (Pubitemid 35216046)
14. Secondary hyperparathyroidism and its therapy as a cardiovascular risk factor among end-stage renal disease patients. Coladonato JA, Ritz E, Adv Ren Replace Ther 2002 9 193 199 10.1053/jarr.2002.34842 12203201 (Pubitemid 34984883)
15. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. Joy MS, Karagiannis PC, Peyerl FW, J Manag Care Pharm 2007 13 397 411 17605511 (Pubitemid 47162414)
16. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM, J Am Soc Nephrol 2004 15 2208 2218 10.1097/01.ASN.0000133041.27682.A2 15284307 (Pubitemid 39031360)
17. Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients. Schumock GT, Andress DL, Marx SE, Sterz R, Joyce AT, Kalantar-Zadeh K, Nephron Clin Pract 2009 113 54 c61 10.1159/000228076 19590235
18. Secondary hyperparathyroidism is associated with higher cost of care among chronic kidney disease patients with cardiovascular comorbidities. Khan S, Nephron Clin Pract 2007 105 159 c164 10.1159/000099006 17259740 (Pubitemid 46492431)
19. EuCliD-a medical registry. Steil H, Amato C, Carioni C, Kirchgessner J, Marcelli D, Mitteregger A, Moscardo V, Orlandini G, Gatti E, Methods Inf Med 2004 43 83 88 15026844
20. An epidemiological study of hemodialysis patients based on the European Fresenius Medical Care Hemodialysis Network: results of the ARO study. de Francisco AL, Kim J, Anker SD, Belozeroff V, Canaud B, Chazot C, Drüeke TB, Eckardt KU, Floege J, Kronenberg F, et al. Nephron Clin Pract 2011 118 143 c154 10.1159/000319936 21150222
21. Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. Wald R, Sarnak MJ, Tighiouart H, Cheung AK, Levey AS, Eknoyan G, Miskulin DC, Am J Kidney Dis 2008 52 531 540 10.1053/j.ajkd.2008.05.020 18657891
22. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Floege J, Kim J, Ireland E, Chazot C, Drüeke T, de Francisco A, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, et al. Nephrol Dial Transplant 2011 26 1948 1955 10.1093/ndt/gfq219 20466670
23. Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. Goodkin DA, Young EW, Kurokawa K, Prütz K-G, Levin NW, Am J Kidney Dis 2004 44 5 Suppl 2 16 21 15486869
24. Using generalized linear models to assess medical care costs. Blough DK, Ramsey SD, Health Serv Outcomes Res Method 2000 1 185 202 10.1023/A: 1012597123667 (Pubitemid 32798848)
25. Linear regression analysis of censored medical costs. Lin DY, Biostatistics 2000 1 35 47 10.1093/biostatistics/1.1.35 12933524 (Pubitemid 33213520)
26. KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the Diagnosis, evaluation, and treatment of CKD-mineral and bone disorder (CKD-MBD). Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ, Sprague SM, Goldfarb S, Am J Kidney Dis 2010 55 773 799 10.1053/j.ajkd.2010.02. 340 20363541
27. Hyperparathyroidism in chronic kidney disease: a retrospective cohort study of costs and outcomes. Smith DH, Johnson ES, Thorp ML, Yang X, Neil N, J Bone Miner Metab 2009 27 287 294 10.1007/s00774-009-0048-8 19333685
28. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM, Kidney Int 2005 68 1793 1800 10.1111/j.1523-1755.2005.00596.x 16164656 (Pubitemid 43169924)
29. Hemoglobin variability does not predict mortality in European hemodialysis patients. Eckardt KU, Kim J, Kronenberg F, Aljama P, Anker SD, Canaud B, Molemans B, Stenvinkel P, Schernthaner G, Ireland E, et al. J Am Soc Nephrol 2010 21 1765 1775 10.1681/ASN.2009101017 20798262